Biomarkers to guide treatment in metastatic renal-cell carcinoma (mRCC) are lacking. Neutrophil-tolymphocyte ratio (NLR) predicts prognosis for mRCC patients receiving targeted therapy. After retrospective chart review of 38 patients with mRCC treated with nivolumab, we found that pretreatment NLR £ 5.5 is associated with superior progression-free survival and overall survival, supporting the notion that NLR is a prognostic biomarker for mRCC. Background: Biomarkers to guide treatment in metastatic renal-cell carcinoma (mRCC) are lacking. We aimed to investigate the association between pretreatment neutrophil-to-lymphocyte ratio (NLR) and outcome of patients with mRCC receiving nivolumab. Patients and Methods: Through retrospective chart review, we identified 38 patients with mRCC treated with standard-of-care nivolumab between 2015 and 2016 at Winship Cancer Institute of Emory University. NLR was determined from complete blood count collected before starting treatment, and imaging was performed to assess progression. The NLR cutoff value of 5.5 was determined by log-rank test, and the univariate association with overall survival (OS) or progression-free survival (PFS) was assessed by the Cox proportional hazard model and Kaplan-Meier method. Results: The 38 patients had a median age of 69 years. The PFS and OS for all patients at 12 months was 54% and 69%, respectively. The median PFS was 2.6 months in the high NLR group but not reached in the low NLR group. Low NLR was strongly associated with increased PFS with hazard ratio of 0.20 (95% confidence interval, 0.07-0.64; P ¼ .006). The median OS was 2.7 months in the high NLR group but not reached in the low NLR group. Low NLR was significantly associated with a prolonged OS with hazard ratio of 0.06 (95% confidence interval, 0.01-0.55; P ¼ .012). Conclusion: Pretreatment NLR < 5.5 is associated with superior PFS and OS. NLR is a biomarker that can inform prognosis for patients with mRCC and should be further validated in larger cohorts and in prospective studies.
Introduction
Therapeutic options for metastatic renal-cell carcinoma (mRCC) have expanded in recent years; patients now have several treatment options with proven clinical benefit. 1 Immune checkpoint inhibition is a novel approach for cancer therapy that has advanced treatment options in mRCC. In particular, PD/PDL1 inhibitors, which target inhibitory pathways on T cells, have been approved for use in treating several advanced malignancies, including mRCC.
survival (OS) benefit, leading to US Food and Drug Administration approval in 2015 for the treatment of mRCC. 4 Given the array of treatment options in mRCC, including antievascular endothelial growth factor (VEGF) tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and now PD/ PDL1 inhibitors, there has been great interest in identifying biomarkers to guide treatment decisions. The neutrophil-tolymphocyte ratio (NLR) is a measure of systemic inflammation that has been reported as a prognostic factor for several solid tumors. 5, 6 A systematic review and meta-analysis of 100 studies of the association of NLR with outcome in solid tumors found that high NLR is associated with poor OS across all tumor subtypes studied, including renal-cell carcinoma. 5 The association of elevated systemic inflammatory markers such as C-reactive protein (CRP) and NLR with worse prognosis is well established in mRCC patients receiving targeted therapy. Previous studies have shown that NLR predicts prognosis in mRCC patients receiving targeted therapy, such as sorafenib or sunitinib. 5, 7 In this study, we aimed to investigate the association between pretreatment NLR and outcome in patients with mRCC receiving standard-of-care nivolumab.
Methods

Patient Data
Through retrospective chart review of Emory electronic health records, we identified 38 patients with mRCC who were treated with nivolumab as standard of care during November 2015 through December 2016 at Winship Cancer Institute of Emory University. Patient demographic data, treatment history, and laboratory data were obtained from a review of progress notes and other records. All patients had complete blood count data collected on the date of initial clinic visit or within 7 days before initiating nivolumab therapy. All blood samples and laboratory tests were collected at the same facility within our institution.
Response Assessment and End Points
Computed tomography or magnetic resonance imaging was performed at baseline and then repeated approximately every 8 to 12 weeks at the discretion of the treating physician. All radiographs were read in the Department of Radiology and Imaging Science at Emory University and reviewed in our clinic. Clinical tumor response was determined during the time of treatment by using Response Evaluation Criteria in Solid Tumors 1.0 according to the patient's medical record. 8 We defined clinical benefit as complete response or partial response, or stable disease of > 4 months. Progression-free survival (PFS) was defined as time from nivolumab initiation to date of progression, hospice enrollment, or death from any cause, whichever was earlier. OS was defined as time from nivolumab initiation to death or hospice enrollment.
Statistical Analysis
Statistical analysis was conducted by SAS 9.4 (SAS Institute, Cary, NC) and by SAS macros developed by the Biostatistics and Bioinformatics Shared Resource at the Winship Cancer Institute. 9 The significance level was set at P < .05. A cutoff value of NLR 5.5 was determined by a bias-adjusted log-rank test after searching all possible cuts (Supplemental Methods in the online version). 10 Throughout this article we refer to NLR 5.5 as low NLR and NLR > 5.5 as high NLR.
The univariate association of each covariate with NLR ( 5.5 vs. > 5.5) was assessed using the chi-square test for categorical covariates and ANOVA for numerical covariates. The univariate association of each covariate with OS or PFS was tested by Cox proportional hazard model, with hazard ratio (HR) and its 95% confidence interval (CI) being reported. In the multivariable analysis, we initially considered several variables in addition to NLR: age, gender, race, tumor histology, baseline albumin, Eastern Cooperative Oncology Group performance status (ECOG PS), Memorial Sloan Kettering Cancer Center (MSKCC) score, baseline platelets greater than the upper limit of normal, and prior nephrectomy. The multivariable model was built by a backward elimination process; a criterion of P > .2 Neutrophil-to-Lymphocyte Ratio and Nivolumab was specified to remove variables that were not significantly predictive. MSKCC risk score, age, race, ECOG PS, baseline platelets, and prior nephrectomy were not predictive of OS or PFS at the prespecified level and were therefore dropped as covariates. The final multivariable analysis included the covariates that had a value of P < .2, which were gender, tumor histology, and baseline albumin. Kaplan-Meier plot along with log-rank test were used to plot OS and PFS stratified by low versus high NLR.
Results
Patient and Tumor Characteristics
The characteristics of 38 patients with mRCC are shown in Table 1 . Patients had a median age of 69 years; 29 (76%) were men and 9 (24%) were women. Within the cohort, tumor histology included 20 (53%) noneclear-cell and 18 (47%) clear-cell disease.
Nephrectomy before nivolumab was common, occurring 30 patients (79%). Thirty-five patients (92%) received prior VEGF inhibitor; however, 2 patients (5%) received treatment other than VEGF inhibitor (mammalian target of rapamycin inhibitor and interleukin-2), and 1 patient (3%) received no prior medical therapy. The majority of patients (45%) had Karnofsky performance status scores of 80 to 100. MSKCC score within the cohort showed 4 patients (10%) with good prognosis, 20 (53%) with intermediate prognosis, and 14 (37%) with poor prognosis.
Response was evaluable for 32 patients; the other 6 patients did not complete 2 cycles (8 weeks) of treatment. One patient experienced complete response, 1 patient partial response, and 15 patients (39%) stable disease. Among those 15 patients with stable disease, 12 patients (80%) had stable disease for > 4 months. In our cohort, a total of 14 patients (37%) had clinical benefit after nivolumab treatment. 
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Baseline NLR and Clinical Benefit
The majority of patients (66%) had low NLR at baseline. According to univariate analysis, baseline low NLR is associated with good (ECOG PS 0-1) performance status (P ¼ .029) but not with any other factors ( Table 2 ). The univariate analysis of clinical benefit from nivolumab showed a significant association with treatment initiation less than 1 year ago (P ¼ .016), but not with any other of the factors studied, including baseline NLR (P ¼ .314) (Supplemental Table 1 in the online version).
Progression-Free Survival
The PFS rate at 12 months was 54% in our cohort. The median PFS was 2.6 months in patients with high NLR but was not reached for patients with low NLR. The Kaplan-Meier curve for PFS is shown in Figure 1A . In univariate analysis, low baseline NLR was significantly associated with longer PFS with a HR of 0.26 (95% CI, 0.09-0.74; P ¼ .012) ( Table 3) . No other variables were significantly associated with PFS. The multivariable analysis showed an adjusted HR of 0.20 (95% CI, 0.07-0.64; P ¼ .006) for low baseline NLR relative to high NLR patients (Table 4) .
Overall Survival
The OS rate at 12 months was 69% in our cohort. The median OS was 2.7 months in patients with high NLR but was not reached for patients with low NLR. The Kaplan-Meier curve for OS is shown in Figure 1B . In the univariate analysis, low NLR was significantly associated with prolonged OS with a HR of 0.06 (95% CI, 0.01-0.049; P ¼ .009) ( Table 5) . In other words, the chance of being alive was 94% among patients with low NLR ( 5.5). Multivariable analysis similarly showed a significant association between NLR and OS, with an adjusted HR of 0.06 (95% CI, 0.01-0.55, P ¼ .012) for low NLR compared to high NLR patients (Table 6 ).
Discussion
The treatment of mRCC has advanced in recent years with the addition of new therapeutic options, most recently immune checkpoint inhibitors such as nivolumab. Consequently, it has become important to develop strategies to determine which patients will benefit from treatment with immunotherapeutic agents. Biomarkers that correlate with disease activity and prognosis are of great interest and have high clinical value; however, a marker to guide treatment of patients with mRCC is lacking. In our study, we found that a baseline NLR of 5.5 before nivolumab treatment was significantly associated with superior PFS and OS among patients with mRCC treated with nivolumab.
Many studies have shown that inflammatory markers such as CRP, albumin, and NLR have prognostic value in mRCC. 7, 11 In one study, the authors monitored CRP before and during sunitinib therapy and found that elevated CRP at baseline was associated with decreased PFS and OS. 12 Furthermore, patients whose CRP normalized during treatment had greater PFS and OS compared to patients whose CRP did not normalize. 12 While limited in scope as a result of small cohorts, such studies show that biomarkers have potential for clinical application. Our group recently reported a prognostic risk assessment model, which includes CRP and albumin for patients with mRCC. 13 In this study, multiple measurements of the inflammatory markers during the course of treatment allowed for risk stratification not only at baseline but also at any time during the course of treatment.
13
NLR is an attractive, cost-effective biomarker that is easily calculated from routine laboratory data. The utility of NLR in renal-cell carcinoma has been previously reported in several studies. A 2015 meta-analysis of 15 cohorts containing over 3000 patients with renal-cell carcinoma showed that elevated NLR indicates poorer prognosis.
14 Another study from 2015 showed that high NLR before nephrectomy for metastatic renal-cell carcinoma was Importantly, the cutoff value defining elevated NLR is different in each of these studies. The NLR values of the individual study cohorts ranged from 2.5 to 4.41 in the 2015 meta-analysis by Hu et al. 13 The authors suggested that studies with NLR 3 as the cutoff had a superior prognostic role; however, it should be noted that the patients in the study cohorts had received nephrectomy or were receiving targeted therapy. 13 Whether the NLR 3 cutoff value is relevant for immune checkpoint inhibitors is not known. In our cohort, we chose the cutoff value of 5.5 based on statistical analysis (Supplemental Methods in the online version). Because these cutoff values were derived statistically from each cohort, it is likely that differences in patient characteristics and treatment factors among cohorts may be responsible for the different cutoff values observed.
The main limitations to our study are the small cohort size and retrospective design, which are susceptible to selection bias in data 
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analysis. However, our results are consistent with previously reported studies in that low NLR values are associated with greater OS and PFS. Our study examined initial NLR before nivolumab therapy as a prognostic factor. Future studies tracking NLR over the course of treatment would be valuable to assess whether NLR changes in response to treatment. Given the multiple retrospective studies showing the prognostic value of NLR for treatment with different agents, it is important to incorporate NLR into a prospective trial to validate its utility in the treatment of advanced renal-cell carcinoma.
In conclusion, we demonstrated that low baseline NLR was associated with superior PFS and OS in patients with mRCC who received nivolumab therapy. These results suggest that NLR can be used as a biomarker for prognosis in patients with mRCC and should be further validated in larger cohorts and in prospective studies.
Clinical Practice Points
NLR is an attractive, cost-effective biomarker that is easily calculated from routine laboratory data. In patients treated with nivolumab, a pretreatment NLR of < 5.5 is associated with superior PFS and OS. Biomarkers such as NLR may help clinical decision making about prognosis in mRCC. These results should be further validated in larger cohorts and in prospective studies. 
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Supplemental Methods
The neutrophil-to-lymphocyte ratio (NLR) cutoff value was determined by statistical methods. The method is based on the logrank test with bias-adjusted P value, which scans all possible cuts in NLR one at a time and picks the one that separates the Kaplan-Meier curve the most. The plot of Martingale residuals shows an overall relationship between the risk of event (progression-free survival [PFS] or overall survival [OS] ) and the continuous NLR (Supplemental Figures 1 and 2, respectively) . Tables show the Q statistics and P value at different cut points; the optimal cut is at 5.54 for both PFS (Supplemental Table 2 ) and OS (Supplemental Table 3 ). For simplicity, we cut NLR as 5.5 versus > 5.5 in the analysis.
Supplemental Figure 1 Outcome, Progression-Free Survival
Baseline Neutrophil-Lymphocyte Ratio 
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Supplemental Outcome considers months to disease progression, death, or hospice.
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Supplemental Outcome considers months death, or hospice.
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